The two phases of the clinical validation of preclinical translational mechanistic research on PDE5 inhibitors since Viagra’s advent. A personal perspective (original) (raw)

• Rajfer J, Aronson WJ, Bush PA, Dorey FJ, Ignarro LJ. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neuro-transmission. N Engl J Med. 1992;326:90–4.
  Article CAS Google Scholar
• Gonzalez-Cadavid NF, Ignarro LJ, Rajfer J. Nitric oxide and the cyclic GMP system in the penis. Mol Urol. 1999;3:51–9.
  CAS Google Scholar
• Vernet D, Ferrini MG, Valente EG, Magee TR, Bou-Gharios G, Rajfer J, et al. Effect of nitric oxide on the differentiation of fibroblasts into myofibroblasts in the Peyronie’s fibrotic plaque and in its rat model. Nitric Oxide. 2002;7:262–76.
  Article CAS Google Scholar
• Valente EG, Vernet D, Ferrini MG, Qian A, Rajfer J, Gonzalez-Cadavid NF. L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie’s fibrotic plaque and related fibroblast cultures. Nitric Oxide. 2003;9:229–44.
  Article CAS Google Scholar
• Davila HH, Magee TR, Vernet D, Rajfer J, Gonzalez-Cadavid NF. Gene transfer of inducible nitric oxide synthase complementary DNA regresses the fibrotic plaque in an animal model of Peyronie’s disease. Biol Reprod. 2004;71:1568–77.
  Article CAS Google Scholar
• Gonzalez-Cadavid NF, Rajfer J. The pleiotropic effects of inducible nitric oxide synthase (iNOS) on the physiology and pathology of penile erection. Curr Pharm Des. 2005;11:4041–6.
  Article CAS Google Scholar
• Ferrini MG, Kovanecz I, Nolazco G, Rajfer J, Gonzalez-Cadavid NF. Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie’s disease. BJU Int. 2006;97:625–33.
  Article CAS Google Scholar
• Gonzalez-Cadavid NF, Rajfer J. Mechanisms of disease: new insights into the cellular and molecular pathology of Peyronie’s disease. Nat Clin Pract Urol. 2005;2:291–7.
  Article CAS Google Scholar
• Gonzalez-Cadavid NF, Rajfer J. Experimental models of Peyronie’s disease. Implications for new therapies. J Sex Med. 2009;6:303–13.
  Article CAS Google Scholar
• Gonzalez-Cadavid NF, Rajfer J. Treatment of Peyronie’s disease with PDE5 inhibitors: an antifibrotic strategy. Nat Rev Urol. 2010;7:215–21.
  Article CAS Google Scholar
• Ralph D, Gonzalez-Cadavid N, Mirone V, Perovic S, Sohn M, Usta M, et al. The management of Peyronie’s disease: evidence-based 2010 guidelines. J Sex Med. 2010;7:2359–74.
  Article Google Scholar
• Ferrini MG, Kovanecz I, Sanchez S, Umeh C, Rajfer J, Gonzalez-Cadavid NF. Fibrosis and loss of smooth muscle in the corpora cavernosa precede corporal veno-occlusive dysfunction (CVOD) induced by experimental cavernosal nerve damage in the rat. J Sex Med. 2009;6:415–28.
  Article CAS Google Scholar
• Ferrini MG, Davila HH, Kovanecz I, Sanchez SP, Gonzalez-Cadavid NF, Rajfer J. Vardenafil prevents fibrosis and loss of corporal smooth muscle that occurs after bilateral cavernosal nerve resection in the rat. Urology. 2006;68:429–35.
  Article Google Scholar
• Ferrini MG, Kovanecz I, Sanchez S, Vernet D, Davila HH, Rajfer J, et al. Long-term continuous treatment with sildenafil ameliorates aging-related erectile dysfunction and the underlying corporal fibrosis in the rat. Biol Reprod. 2007;76:915–23.
  Article CAS Google Scholar
• Kovanecz I, Rambhatla A, Ferrini M, Vernet D, Sanchez S, Rajfer J, et al. Long-term continuous sildenafil treatment ameliorates corporal veno-occlusive dysfunction (CVOD) induced by cavernosal nerve resection in rats. Int J Impot Res. 2008;20:202–12.
  Article CAS Google Scholar
• Kovanecz I, Rambhatla A, Ferrini MG, Vernet D, Sanchez S, Rajfer J, et al. Chronic daily tadalafil prevents the corporal fibrosis and veno-occlusive dysfunction that occurs after cavernosal nerve resection. BJU Int. 2008;101:203–10.
  CAS Google Scholar
• Kovanecz I, Rivera S, Nolazco G, Vernet D, Segura D, Gharib S, et al. Separate or combined treatments with daily sildenafil, molsidomine, or muscle-derived stem cells prevent erectile dysfunction in a rat model of cavernosal nerve damage. J Sex Med. 2012;9:2814–26.
  Article CAS Google Scholar
• Gonzalez-Cadavid NF. Mechanisms of penile fibrosis. J Sex Med. 2009;6(Suppl 3):353–62.
  Article Google Scholar
• Sáenz de Tejada I, Angulo J, Cellek S, González-Cadavid N, Heaton J, Pickard R. Simonsen U pathophysiology of erectile dysfunction. J Sex Med. 2005;2:26–39.
  Article Google Scholar
• Rambhatla A, Kovanecz I, Ferrini M, Gonzalez-Cadavid NF, Rajfer J. Rationale for phosphodiesterase 5 inhibitor use post-radical prostatectomy: experimental and clinical review. Int J Impot Res. 2008;20:30–4.
  Article CAS Google Scholar
• Bivalacqua TJ, Diner EK, Novak TE, Vohra Y, Sikka SC, Champion HC, et al. A rat model of Peyronie’s disease associated with a decrease in erectile activity and an increase in inducible nitric oxide synthase protein expression. J Urol. 2000;163:1992–8.
  Article CAS Google Scholar
• Lee KC, Brock GB. Daily dosing of PDE5 inhibitors: where does it fit in? Curr Urol Rep. 2013;14:269–78.
  Article Google Scholar
• Egydio PH, Kuehhas FE. Treatments for fibrosis of the corpora cavernosa. Arab J Urol. 2013;11:294–8.
  Article Google Scholar
• Burnett AL. Molecular pharmacotherapeutic targeting of PDE5 for preservation of penile health. J Androl. 2008;29:3–14.
  Article CAS Google Scholar
• Jaeger VK, Walker UA. Erectile dysfunction in systemic sclerosis. Curr Rheumatol Rep. 2016;18:49 https://doi.org/10.1007/s11926-016-0597-5
  Article Google Scholar
• Iacono F, Prezioso D, Ruffo A, Illiano E, Romis L, Di Lauro G, et al. Testosterone deficiency causes penile fibrosis and organic erectile dysfunction in aging men. Evaluating association among age, TDS and ED. BMC Surg. 2012;12(Suppl 1):S24.
  Article Google Scholar
• El-Sakka AI. Alleviation of post-radical prostatectomy cavernosal fibrosis: future directions and potential utility for PDE5 inhibitors. Expert Opin Investig Drugs. 2011;20:1305–9.
  Article CAS Google Scholar
• Vignozzi L, Filippi S, Comeglio P, Cellai I, Morelli A, Maneschi E, et al. Tadalafil effect on metabolic syndrome-associated bladder alterations: an experimental study in a rabbit model. J Sex Med. 2014;11:1159–72.
  Article CAS Google Scholar
• Martínez-Salamanca JI, Zurita M, Costa C, Martínez-Salamanca E, Fernández A, Castela A, et al. Dual strategy with oral phosphodiesterase type 5 inhibition and intracavernosal implantation of mesenchymal stem cells is superior to individual approaches in the recovery of erectile and cavernosal functions after cavernous nerve injury in rats. J Sex Med. 2016;13:1–11.
  Article Google Scholar
• Wang JS, Kovanecz I, Vernet D, Nolazco G, Kopchok GE, Chow SL, et al. Effects of sildenafil and/or muscle derived stem cells on myocardial infarction. J Transl Med. 2012;10:159 https://doi.org/10.1186/1479-5876-10-159
  Article CAS Google Scholar
• Ferrini MG, Rivera S, Moon J, Vernet D, Rajfer J, Gonzalez-Cadavid NF. The genetic inactivation of inducible nitric oxide synthase (iNOS) intensifies fibrosis and oxidative stress in the penile corpora cavernosa in type 1 diabetes. J Sex Med. 2010;7:3033–44.
  Article CAS Google Scholar
• Ferrini MG, Davila HH, Valente EG, Gonzalez-Cadavid NF, Rajfer J. Aging-related induction of inducible nitric oxide synthase is vasculo-protective to the arterial media. Cardiovasc Res. 2004;61:796–805.
  Article CAS Google Scholar
• Ferrini MG, Nolazco G, Vernet D, Gonzalez-Cadavid NF, Berman J. Increased vaginal oxidative stress, apoptosis, and inducible nitric oxide synthase in a diabetic rat model: implications for vaginal fibrosis. Fertil Steril. 2006;86(4 Suppl):1152–63.
  Article CAS Google Scholar